NEW YORK (GenomeWeb News) - Luminex has granted EMD Chemicals, a subsidiary of Germany’s Merck KGaA, a license to develop multiplex immunoassays for the xMAP technology platform, EMD said last week.
EMD said it plans to develop multiplex assays for the xMAP under its Novagen brand to detect the phosphorylation status of proteins in disease-related signaling pathways.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.